TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

22 Oct 2024 13:30:00 By Nasdaq GlobeNewswire

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

21 Oct 2024 14:58:22 By Nasdaq GlobeNewswire

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

21 Oct 2024 12:56:12 By Nasdaq GlobeNewswire

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

18 Oct 2024 21:46:52 By Nasdaq GlobeNewswire

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

17 Oct 2024 08:32:57 By Nasdaq GlobeNewswire

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

17 Oct 2024 06:54:51 By Nasdaq GlobeNewswire

Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality

16 Oct 2024 15:30:14 By Nasdaq GlobeNewswire

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

15 Oct 2024 13:30:57 By Nasdaq GlobeNewswire

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

15 Oct 2024 10:36:13 By Nasdaq GlobeNewswire

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

14 Oct 2024 17:43:44 By Nasdaq GlobeNewswire

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

11 Oct 2024 14:59:39 By Nasdaq GlobeNewswire

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

11 Oct 2024 11:12:04 By Nasdaq GlobeNewswire

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

08 Oct 2024 13:40:05 By Nasdaq GlobeNewswire

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

24 Sep 2024 10:09:57 By Nasdaq GlobeNewswire

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 Aug 2024 11:17:01 By Nasdaq GlobeNewswire

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

09 Aug 2024 10:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

11 Jul 2024 11:21:21 By Nasdaq GlobeNewswire